Dear Colleagues,

We are in the midst of a revolution in the prevention and management of cardiovascular disease, with the emergence of new drugs and new targets associated with improved cardiovascular outcomes. At the same time, advances in risk assessment, including novel biomarkers, genetics, and noninvasive subclinical atherosclerosis imaging represent major advances that will be implemented more widely in the coming years. Issues related to primary and secondary prevention are becoming increasing complex, and more and more patients are seeking specialized advice on cardiovascular risk assessment and management. This issue of Reviews in Cardiovascular Medicine tackles these bold issues and provides a glimpse into the next frontiers in prevention of cardiovascular disease.

Prof. Dr.  Michael D. Shapiro

Guest Editor